Researchers in the Netherlands tested the vaccine -- which infuses a patient’s own dendritic cells with antigen from the patient’s tumor -- on 10 patients and found that it induced an immune T-cell response against mesothelioma tumors. This is the first time DC-based immunotherapy has been tested in patients with mesothelioma, which typically occurs in the lungs but can arise at ot...